| Bioactivity | LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism[1]. |
| Target | EC50: 55 nM (OT-R)Ki: 226 nM (OT-R) |
| Invitro | In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only[1]. |
| In Vivo | LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD )[1]. Animal Model: |
| Name | LIT-001 |
| CAS | 2245072-21-1 |
| Formula | C30H34F3N7O4S |
| Molar Mass | 645.70 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Frantz MC, et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem. 2018 Oct 11;61(19):8670-8692. |
LIT-001
CAS: 2245072-21-1 F: C30H34F3N7O4S W: 645.70
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social intera
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.